Vascular Cell Adhesion Molecule-1 (VCAM-1) in Graves' Disease: Its Association to Thyroid Status and Thyroid Receptor Stimulating Antibodies

month. Serum sVCAM-1 levels were significantly elevated in TRAb+ patients compared to TRAb- (860 versus 499 ng/mL, p<0.001). The level decreased significantly to 537 ng/mL with treatment but remained higher than in TRAb- patients (p=0.003). Irrespective of TRAb status, all but one patient had elevated serum sICAM-1 levels that remained unaffected by carbimazole therapy. In contrast, IL-6 levels of hyperthyroid patients were within the reference range of 1.4-14.1 pg/mL. Baseline and post-treatment sVCAM-1, and not TRAb levels, were significantly correlated to thyroid hormones. Conclusion: Compared to other inflammatory markers, sVCAM-1 showed significant correlation to thyroid stimulating antibodies and was most sensitive to changes in thyroid status. The significance of these findings in relation to Graves’ disease warrants further investigation.

[1]  K. Usadel,et al.  Expression of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 and homing factor CD44 after engraftment of Graves' lymphocytes in xenotransplanted human thyroid tissue in athymic nude mice. , 2001, Thyroid : official journal of the American Thyroid Association.

[2]  B. Rapoport,et al.  The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies , 1998 .

[3]  T. Davies.  Thyroid-Stimulating Antibodies Predict Hyperthyroidisma , 1998 .

[4]  L. Braverman,et al.  TSH Receptor Antibody Measurement in the Diagnosis and Management of Graves’ Disease Is Rarely Necessaryb , 1998 .

[5]  J. Wortsman,et al.  Thyrotropin receptor epitopes recognized by graves' autoantibodies developing under immunosuppressive therapy. , 1998, The Journal of clinical endocrinology and metabolism.

[6]  A. Bellastella,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  L. Braverman,et al.  Thyroid controversy--stimulating antibodies. , 1998, The Journal of clinical endocrinology and metabolism.

[8]  B. Rapoport,et al.  The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. , 1998, Endocrine reviews.

[9]  A. Pinchera,et al.  Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. , 1998, The Journal of clinical endocrinology and metabolism.

[10]  C. Massart,et al.  Expression of membrane and soluble intercellular adhesion molecule-1 in Graves' disease. , 1997, Journal of molecular endocrinology.

[11]  C. Oshiro,et al.  Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects , 1997, Journal of endocrinological investigation.

[12]  A. Pinchera,et al.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. , 1997, Thyroid : official journal of the American Thyroid Association.

[13]  M. Taşar,et al.  Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels. , 1996, Thyroid : official journal of the American Thyroid Association.

[14]  村上 康弘.  Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome , 1996 .

[15]  K. Mori,et al.  Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status. , 1995, Thyroid : official journal of the American Thyroid Association.

[16]  W. Graninger,et al.  Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[17]  A. Bellastella,et al.  Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. , 1995, The Journal of clinical endocrinology and metabolism.

[18]  W. Graninger,et al.  Soluble endothelium‐associated adhesion molecules in patients with Graves' disease , 1994, Clinical and experimental immunology.

[19]  G S Levey,et al.  Treatment of Hyperthyroid Disease , 1994, Annals of Internal Medicine.

[20]  J. Franklyn.  The management of hyperthyroidism. , 1994, The New England journal of medicine.

[21]  S. Nagataki,et al.  The expression of adhesion molecules in thyroid glands from patients with Graves' disease. , 1994, Thyroid : official journal of the American Thyroid Association.

[22]  P. Carayon,et al.  Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. , 1994, The Journal of clinical endocrinology and metabolism.

[23]  A. Heufelder,et al.  Soluble intercellular adhesion molecule‐1 (sICAM‐1) in sera of patients with Graves’ ophthalmopathy and thyroid diseases , 1993, Clinical and experimental immunology.

[24]  A. Gearing,et al.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. , 1992, Biochemical and biophysical research communications.

[25]  Hong-Kyu Lee,et al.  Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease , 1992, Clinical endocrinology.

[26]  R. Pujol-Borrell,et al.  Expression of intercellular adhesion molecule-1 in thyroid follicular cells in autoimmune, non-autoimmune and neoplastic diseases of the thyroid gland: discordance with HLA. , 1992, Journal of autoimmunity.

[27]  M. Feldmann,et al.  Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. , 1990, Journal of autoimmunity.

[28]  R. Tizard,et al.  Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes , 1989, Cell.

[29]  T. Springer,et al.  Functional evidence that intercellular adhesion molecule‐1 (icam‐1) is a ligand for lfa‐1d‐ependent adhesion in t cell‐mediated cytotoxicity , 1988, European journal of immunology.

[30]  K. Burman,et al.  Immune mechanisms in Graves' disease. , 1985, Endocrine reviews.

[31]  A. Guerrier,et al.  THYROID STIMULATING ANTIBODIES: AN AID TO THE STRATEGY OF TREATMENT OF GRAVES' DISEASE? , 1984, Clinical endocrinology.

[32]  A. McGregor,et al.  Autoimmune thyroid disease: developments in our understanding. , 1984, Endocrine reviews.